Medicine capable of reducing uric acid content in blood

A drug and uric acid technology, applied in the field of drugs for reducing the concentration of uric acid in blood, can solve problems such as reducing the therapeutic effect, and achieve the effects of far-reaching social significance, high safety, and huge economic value.

Inactive Publication Date: 2009-03-25
INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This technology prevents certain types of bacillus called uricase (urea) by killing them with an activator like citrate salt. It also uses specialized materials made into tiny particles for embedding these cells inside capsule shells containing active Urology Bacteroides fragile X lycopsis virus type 1(UV-3). These encased cellular structures help protect against harmful substances such as hydrogen peroxide produced during metabolism while still being able to release their catalyst quickly enough. Overall this results in safer and more effective drugs than current methods used alone.

Problems solved by technology

This patented technical problem addressed in this patents relates to improving methods for administering biological agents like proteins and peptides without causing side effects due to their rapid breakdown rate when taken up outside the gastrointestinal tract. Current therapies involve either expensive ingestion or slow release formulations containing these compounds, making them difficult to use over time.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine capable of reducing uric acid content in blood
  • Medicine capable of reducing uric acid content in blood
  • Medicine capable of reducing uric acid content in blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1, the construction of the engineering bacterium expressing urate oxidase

[0037] 1. Acquisition of urate oxidase gene (UOX)

[0038] (1) Acquisition of AUOX gene

[0039] 1. Genomic DNA extraction

[0040] Under sterile conditions, scrape the mycelium from the slant culture medium of Aspergillus flavus 3.1398 (China Common Microorganism Culture Collection Management Center) and insert it into 5ml Czapek's medium (sucrose 30g / L, NaNO 3 3g / L, MgSO4 ·7H 2 O 0.5g / L, KCl 0.5g / L, FeSO 4 ·7H 2 O 0.01g / L, K 2 HPO 4 ·2H 2 O 1.0g / L, peptone 15g / L; pH6.0-6.5), cultured at 30°C for 5 days. Take 2ml of the bacterial liquid to collect the flocculent bacterial cells by centrifugation, wash the precipitate once with sterile water; put the bacterial cells into a sterile mortar, pour about 20ml of liquid nitrogen into it for quick freezing, and grind the bacterial cells quickly when the liquid nitrogen has just evaporated. into a powder form; add 200 μl of yeast ly...

Embodiment 2

[0111] Embodiment 2, prepare microcapsule medicine with engineering bacterium

[0112] One, prepare microcapsule medicine with engineering bacteria I

[0113] (1) Formaldehyde inactivation

[0114] 1. Effect of formaldehyde inactivation on the ability of engineering bacteria to degrade uric acid

[0115] The selection of formaldehyde inactivation conditions refers to the "China Biological Products Regulations" 2000 edition (page 110). The final concentration of formaldehyde is generally between 1% (volume ratio) and 2% (volume ratio). The formaldehyde of % (volume ratio) and 2% (volume ratio) deactivates engineering bacteria I, and concrete steps are as follows:

[0116] Put 1 gram of wet bacteria in 25ml formaldehyde-physiological saline solution system (1% or 2% formaldehyde concentration), shake at 30°C or 37°C (200 rpm) for 30min. Samples were taken at the beginning, 10min, 15min, 20min, and 30min to determine the ability of the bacteria to degrade uric acid and the rep...

Embodiment 3

[0139] Embodiment 3, the property determination of microcapsule medicine

[0140] The experiments in this embodiment were all repeated three times, and the results were averaged.

[0141] 1. Determination of properties of microcapsule drug A

[0142] 1. The mechanical stability of the drug in gastrointestinal fluid

[0143] The prepared microcapsule drug A of Example 2 was respectively placed in normal saline, artificial gastric juice (dilute hydrochloric acid 16.4ml, add about 800ml of water and pepsin 10g, after shaking up, add water and release to 100ml), artificial intestinal juice ( Take 6.8g of potassium dihydrogen phosphate, add 500ml of water to dissolve, adjust the pH value to 6.8 with 0.1mol / L sodium hydroxide solution, take 10g of trypsin, add water to dissolve, mix the two liquids, add water to dilute to 1000ml) , 37°C, oscillating at 200 rpm, sampling every 24 hours, detecting microcapsule rupture in each solution with a microscope and taking pictures.

[0144]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicine for lowering the concentration of uric acid in blood. The medicine provided by the invention and used for lowering the concentration of uric acid in blood has active ingredient of inactivated microorganisms for the expression of urate oxidase; urate oxidase comes from microorganisms, animals or plants. The invention enables engineering bacteria used for expressing urate oxidase to be embedded in micro-capsules and solves the problem of high treatment cost in oral micro-encapsulated urate oxidase. The invention inactivates the engineering bacteria used for expressing urate oxidase and enables the engineering bacteria to lose the reproductive capacity in the premise of maintaining the activity of urate oxidase so that the medicine has high safety. The medicine is orally taken for the treatment of hyperuricemia, so as to avoid the influence on the activity of urate oxidase caused by acid-base intestinal environment; besides, the balance among intestinal flora is not broken even a small amount of thalli is accidentally released from the micro-capsules.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap